Pfizer has given up on its attempt to take over the British pharmaceutical company AstraZeneca.
The American drug maker announced Monday that it was withdrawing its latest in a series of unsolicited offers.
That bid valued AstraZeneca (AZN) at nearly $120 billion, a 45% premium over the company's share price in mid-April. If the deal had been accepted, it would have been one of the biggest drug takeovers in history.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity